Literature DB >> 3072212

Opioids and non-opioid enantiomers selectively attenuate N-methyl-D-aspartate neurotoxicity on cortical neurons.

D W Choi1, V Viseskul.   

Abstract

Addition of 1 microM-1 mM methadone to the bathing medium produced a concentration-dependent reduction in the neurotoxicity of exogenously applied N-methyl-D-aspartate (NMDA) in murine cortical cell culture (EC50 about 100 microM); the reduction persisted at intense NMDA exposure, consistent with non-competitive inhibition. Methadone also protected against exposure to quinolinate but not quisqualate or kainate. Concentrations (100 microM-3 mM) of several other opioids - morphine, fentanyl, codeine, meperidine, dextropropoxyphene, and naltrexone - were additionally found to produce concentration-dependent reductions in NMDA neurotoxicity. This novel neuron-protective effect of opioids was not mediated by conventional opioid receptors: the non-opioid enantiomer of methadone and morphine exhibited a potency equal to or greater than that of the opioid enantiomer, and 1 mM naloxone did not act as an antagonist. The possibility that opioids, or especially non-opioid enantiomers of opioids, might provide a useful therapeutic approach in diseases states involving NMDA receptor-mediated neurotoxicity, warrants further study.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3072212     DOI: 10.1016/0014-2999(88)90399-8

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  11 in total

1.  The assessment and management of agitation and delirium in the general hospital.

Authors:  Theodore A Stern; Christopher M Celano; Anne F Gross; Jeff C Huffman; Oliver Freudenreich; Nicholas Kontos; Shamim H Nejad; Jennifer Repper-Delisi; B Taylor Thompson
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

Review 2.  Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia.

Authors:  Mark R Hutchinson; Yehuda Shavit; Peter M Grace; Kenner C Rice; Steven F Maier; Linda R Watkins
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

3.  A novel insight into neuroprotection against hypoxic/ischemic stress.

Authors:  Yuan Feng; Dongman Chao; Xiaozhou He; Yilin Yang; Xuezhi Kang; Lawrence H Lazarus; Ying Xia
Journal:  Sheng Li Xue Bao       Date:  2009-12-25

4.  Activation of µ-opioid receptors and block of Kir3 potassium channels and NMDA receptor conductance by L- and D-methadone in rat locus coeruleus.

Authors:  Aya Matsui; John T Williams
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 5.  Neuroprotection against hypoxia/ischemia: δ-opioid receptor-mediated cellular/molecular events.

Authors:  Xiaozhou He; Harleen K Sandhu; Yilin Yang; Fei Hua; Nathalee Belser; Dong H Kim; Ying Xia
Journal:  Cell Mol Life Sci       Date:  2012-09-27       Impact factor: 9.261

Review 6.  Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.

Authors:  Jörn Lötsch; Carsten Skarke; Jürgen Liefhold; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

7.  Pharmacogenetics of Addiction Therapy.

Authors:  David P Graham; Mark J Harding; David A Nielsen
Journal:  Methods Mol Biol       Date:  2022

8.  Biologically active MK-801 and SKF-10,047 binding sites distinct from those in rat brain are expressed on human lung cancer cells.

Authors:  R Maneckjee; J D Minna
Journal:  Mol Biol Cell       Date:  1992-06       Impact factor: 4.138

9.  Nonconventional opioid binding sites mediate growth inhibitory effects of methadone on human lung cancer cells.

Authors:  R Maneckjee; J D Minna
Journal:  Proc Natl Acad Sci U S A       Date:  1992-02-15       Impact factor: 11.205

Review 10.  Ionic storm in hypoxic/ischemic stress: can opioid receptors subside it?

Authors:  Dongman Chao; Ying Xia
Journal:  Prog Neurobiol       Date:  2009-12-28       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.